Long Noncoding RNA MNX1-AS1 Knockdown Inhibits Cell Proliferation and Migration in Ovarian Cancer
Authors: Fengling Li
Huan Li
Yan Lv
Peishu Liu
Xinrui Zhao
Journal: Cancer Biotherapy and Radiopharmaceuticals (2017)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: apoptosis; cell cycle; cell proliferation; lncRNA MNX1-AS1; ovarian cancer.
Affiliations: 1 Department of Obstetrics and Gynaecology, Qilu Hospital of Shandong University , Jinan, China ., 2 Department of Obstetrics and Gynaecology, Zhongxin Hospital of Huizhou , Huizhou, China ., 3 Department of Obstetrics and Gynaecology, Beijing University Shenzhen Hospital , Shenzhen, China ., 4 Department of Obstetrics and Gynaecology, Yantai Affiliated Hospital of Binzhou Medical University , Yantai, China .

Abstract:  Long noncoding RNAs (lncRNAs) have recently emerged as pivotal regulators that govern fundamental biological processes and disease pathogenesis. LncRNA MNX1-AS1 has been reported to promote cell proliferation and invasion in gallbladder cancer, but its biological role and regulatory mechanism in ovarian cancer are poorly defined. In this study, it was found that higher expression of lncRNA MNX1-AS1 is closely associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in ovarian cancer patients. RNA interference (RNAi) to downregulate the expression of lncRNA MNX1-AS1 was used in the ovarian cancer cell lines, OVCA433 and SKOV-3. CCK-8, EdU staining, and colony formation assays was used to test the viability and proliferation ability of these cells. Wound healing and transwell migration assays were performed to determine the migration ability of the cells. Cell cycle progression and apoptotic assays were carried out using flow cytometry. These in vitro loss-of-function experiments revealed that downregulation of lncRNA MNX1-AS1 suppressed cell proliferation, colony formation, cell migration ability, induced cell cycle arrest at the G0/G1 phase, and promoted apoptosis. Furthermore, MNX1-AS1 knockdown altered the protein expressions of CDK4, cyclin D, Bax, and Bcl-2. These findings demonstrated for the first time that lncRNA MNX1-AS1 functions as an oncogene in ovarian cancer and could be a potential target for this disease. 

Retracted: No

PubPeer comments:
 Article was retracted. Retraction notice: The Editor has retracted this article because there is significant overlap of figures and text with [10.1038 srep29589]. Specifically: Figure 1a [1] appears to be identical with sub panels in Figs. 1b and 1d [2] Figure 1d [1] appears to be identical with a sub-panel in Fig. 1e [2] Figures 2a and 2b [1] appears to be identical with Fig. 2a [2] Figures 2c, 2d, 4a, 4b and 4c in [1] appear to be identical with Figs. 2c, 2d, 4a, 4b and 4c in [2] Figure 3a [1] appears to be identical with Fig. 3b [2] Figure 3b [1] appears to be identical with Fig. 3c [2] Figures 5a, 5c, 5d and 5f in [1] appear to be identical with Figs. 6a, 6b, 6c and 6d in [2], respectively Figure 6b [1] appears to be identical with Fig. 8a [2] The Editor therefore has no confidence in this article. The authors have told us that all the Western blots in this article were produced by an external experimental company; this was not stated in the article. [All authors agree with this retraction.] https: www.nature.com articles s41401-020-0363-0 ,